aTyr Pharma Q3 EPS $(0.46), Inline

aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.46) per share which met the analyst consensus estimate. This is a 9.52 percent decrease over losses of $(0.42) per share from the same period last year.

aTyr Pharma (NASDAQ:LIFE) reported quarterly losses of $(0.46) per share which met the analyst consensus estimate. This is a 9.52 percent decrease over losses of $(0.42) per share from the same period last year.

Total
0
Shares
Related Posts
Read More

Reported Late Thursday, Theratechnologies Announces Update From Ongoing TH1902 Study; Decided To Pause The Enrollment Of Patients In Its Phase 1 Clinical Trial Of Th1902; Plans To Submit An Amendment To Its Protocol To The U.S. FDA For Approval

Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today

THTX